Lifecore Biomedical, Inc. LFCR Income Statement
| TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | TTM Q4 '24 | ||
|---|---|---|---|---|---|---|
| $128.87M+0.5% | $130.31M+7.2% | $130.86M+16.5% | $128.45M+23.4% | $128.26M+24.2% | ||
| $88.57M+2.5% | $86.72M-2.7% | $85.22M+2.3% | $83.94M+5.8% | $86.41M+14.8% | ||
| $40.3M-3.7% | $43.59M+34.7% | $45.64M+57.3% | $44.51M+80.0% | $41.85M+49.5% | ||
| 31.3%-1.4pp | 33.4%+6.8pp | 34.9%+9.1pp | 34.7%+10.9pp | 32.6%+5.5pp | ||
| $8.26M-3.7% | $8.32M-2.5% | $8.44M-1.8% | $8.62M-0.7% | $8.58M-1.9% | ||
| $44.86M+10.5% | $48.11M+18.3% | $47.98M+16.7% | $46.2M+15.3% | $40.61M+4.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | -$1.28M+54.1% | -$2.42M-30.1% | -$3.09M-173% | -$3.05M-163% | ||
| -$38.67M— | —— | —— | —— | —— | ||
| $43K— | —— | —— | —— | —— | ||
| -$38.72M— | —— | —— | —— | —— | ||
| -30%— | —— | —— | —— | —— | ||
| -$1.23— | —— | —— | —— | —— | ||
| -$15.66M— | —— | —— | —— | —— | ||
| -12.2%— | —— | —— | —— | —— | ||
| -$23.69M— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Lifecore Biomedical, Inc.'s revenue?
- Lifecore Biomedical, Inc. (LFCR) generated $125.9M in revenue over the trailing twelve months, down 3.8% year over year.
- Is Lifecore Biomedical, Inc. profitable?
- Lifecore Biomedical, Inc. is not currently profitable: it reported a net loss of $40.9M over the trailing twelve months, a -30.0% net margin.
- What are Lifecore Biomedical, Inc.'s profit margins?
- Gross margin is 31.3% and operating margin is -14.5%, with a -30.0% net margin.
- What is Lifecore Biomedical, Inc.'s earnings per share?
- Lifecore Biomedical, Inc.'s diluted EPS over the trailing twelve months is $-1.17.
- Where does Lifecore Biomedical, Inc.'s income statement data come from?
- Every line is extracted from Lifecore Biomedical, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
